WO2000021981A3 - PEPTIDES FIXANT LE TNFα ET LEUR APPLICATION POUR LA DETECTION, LA DESACTIVATION ET L'ELIMINATION DU TNFα DE LIQUIDES BIOLOGIQUES - Google Patents

PEPTIDES FIXANT LE TNFα ET LEUR APPLICATION POUR LA DETECTION, LA DESACTIVATION ET L'ELIMINATION DU TNFα DE LIQUIDES BIOLOGIQUES Download PDF

Info

Publication number
WO2000021981A3
WO2000021981A3 PCT/DE1999/003256 DE9903256W WO0021981A3 WO 2000021981 A3 WO2000021981 A3 WO 2000021981A3 DE 9903256 W DE9903256 W DE 9903256W WO 0021981 A3 WO0021981 A3 WO 0021981A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnfα
deactivating
utilization
detecting
biological fluids
Prior art date
Application number
PCT/DE1999/003256
Other languages
German (de)
English (en)
Other versions
WO2000021981A2 (fr
Inventor
Heinz-Juergen Wagner
Hans-Werner Heinrich
Udo Meyer
Original Assignee
Bioserv Ag
Wagner Heinz Juergen
Heinrich Hans Werner
Meyer Udo Aquaconsult Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioserv Ag, Wagner Heinz Juergen, Heinrich Hans Werner, Meyer Udo Aquaconsult Gmbh filed Critical Bioserv Ag
Publication of WO2000021981A2 publication Critical patent/WO2000021981A2/fr
Publication of WO2000021981A3 publication Critical patent/WO2000021981A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des peptides de formule NH2-IQTLHAQ-COOH et NH2-RLANTHFVY-COOH qui fixent spécifiquement le TNFα in vitro et ex vivo. Les peptides selon l'invention conviennent à la production de systèmes de test du TNFα, à la désactivation du TNFα et à la l'élimination du TNFα des liquides du corps par plasmaphérèse, par exemple.
PCT/DE1999/003256 1998-10-09 1999-10-08 PEPTIDES FIXANT LE TNFα ET LEUR APPLICATION POUR LA DETECTION, LA DESACTIVATION ET L'ELIMINATION DU TNFα DE LIQUIDES BIOLOGIQUES WO2000021981A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19847935 1998-10-09
DE19847935.2 1998-10-09

Publications (2)

Publication Number Publication Date
WO2000021981A2 WO2000021981A2 (fr) 2000-04-20
WO2000021981A3 true WO2000021981A3 (fr) 2000-07-20

Family

ID=7884809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1999/003256 WO2000021981A2 (fr) 1998-10-09 1999-10-08 PEPTIDES FIXANT LE TNFα ET LEUR APPLICATION POUR LA DETECTION, LA DESACTIVATION ET L'ELIMINATION DU TNFα DE LIQUIDES BIOLOGIQUES

Country Status (2)

Country Link
DE (1) DE19948867A1 (fr)
WO (1) WO2000021981A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104829697B (zh) * 2015-05-04 2018-09-04 国家纳米科学中心 一种与肿瘤坏死因子结合的多肽及其应用
CN106831944A (zh) * 2017-01-12 2017-06-13 复旦大学 一种肿瘤坏死因子alpha的高亲和性肽及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393438A2 (fr) * 1989-04-21 1990-10-24 Synergen, Inc. Récepteur du TNF, protéine liant le TNF at ADN codant pour ceux-ci
EP0398327A1 (fr) * 1989-05-18 1990-11-22 Yeda Research And Development Company Limited Protéine de liaison II au facteur de nécrose tumorale, sa purification et anticorps spécifiques
EP0417563A2 (fr) * 1989-09-12 1991-03-20 F. Hoffmann-La Roche Ag Protéines qui lient le TNF
WO1992017583A1 (fr) * 1991-03-29 1992-10-15 Immunex Corporation Antagonistes de cytokines a base de proteines virales isolees
DE4342846A1 (de) * 1993-12-10 1995-06-14 Schering Ag Tumor-Nekrose-Faktor-alpha inaktivierende Peptide
US5753628A (en) * 1995-06-07 1998-05-19 Centocor, Inc. Peptide inhibitors of TNF containing predominantly D-amino acids
WO1998053842A1 (fr) * 1997-05-30 1998-12-03 The Trustees Of The University Of Pennsylvania Analogues de peptides derives de recepteurs de facteur de necrose des tumeurs

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393438A2 (fr) * 1989-04-21 1990-10-24 Synergen, Inc. Récepteur du TNF, protéine liant le TNF at ADN codant pour ceux-ci
EP0398327A1 (fr) * 1989-05-18 1990-11-22 Yeda Research And Development Company Limited Protéine de liaison II au facteur de nécrose tumorale, sa purification et anticorps spécifiques
EP0417563A2 (fr) * 1989-09-12 1991-03-20 F. Hoffmann-La Roche Ag Protéines qui lient le TNF
WO1992017583A1 (fr) * 1991-03-29 1992-10-15 Immunex Corporation Antagonistes de cytokines a base de proteines virales isolees
DE4342846A1 (de) * 1993-12-10 1995-06-14 Schering Ag Tumor-Nekrose-Faktor-alpha inaktivierende Peptide
US5753628A (en) * 1995-06-07 1998-05-19 Centocor, Inc. Peptide inhibitors of TNF containing predominantly D-amino acids
WO1998053842A1 (fr) * 1997-05-30 1998-12-03 The Trustees Of The University Of Pennsylvania Analogues de peptides derives de recepteurs de facteur de necrose des tumeurs

Also Published As

Publication number Publication date
WO2000021981A2 (fr) 2000-04-20
DE19948867A1 (de) 2000-08-17

Similar Documents

Publication Publication Date Title
DE60217264D1 (de) Filtersystem für Blutgefässe
EP2267015A3 (fr) Polypeptides de liaison pour la protéine stimulatrice des lymphocytes B (BLyS)
WO2003057134A3 (fr) Agents de liaison specifiques de l'angiopoietine-2 humaine
ATE364386T1 (de) (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom
EP2289944A3 (fr) Anticorps bispécifiques substituant des protéines fonctionnelles
NO20003525L (no) Biologisk væskebehandlingssystem
AU2001276344A1 (en) System for removing body fluid, especially blood
WO2001047959A3 (fr) Molecules d'acides nucleiques isoles codant pour des antigenes associes au cancers, ces antigenes et leur utilisation
MXPA03009251A (es) Un procedimiento para eliminar azufre de la fraccion diesel.
EP1122309A4 (fr) Supports utilises pour immobiliser de l'adn ou autre
WO1996027665A3 (fr) Proteines ayant les proprietes d'un facteur silenceur exerçant une action de repression sur les neurones
MXPA01011182A (es) Metodos, composiciones y conjuntos para indicador biologico de esterilizacion.
ZA975588B (en) Isolated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof.
WO1999054349A3 (fr) Molecules d'acides nucleiques dermatophagoides, proteines et leurs utilisations
WO2000021981A3 (fr) PEPTIDES FIXANT LE TNFα ET LEUR APPLICATION POUR LA DETECTION, LA DESACTIVATION ET L'ELIMINATION DU TNFα DE LIQUIDES BIOLOGIQUES
WO2001041813A3 (fr) Procedes de traitement de lupus sur la base de l'affinite aux anticorps et procedes de criblage et compositions associees
WO2000039154A8 (fr) Peptides du recepteur at1 et son utilisation en cas de preeclampsie et d'hypertension maligne
DE69811677D1 (de) Verfahren zur präparation von enantiomer-angereicherten, n-derivatisierten laktamen.
WO2001032693A3 (fr) Proteine mtr1 apparentee aux proteines trp et sequence adn codant pour celle-ci
WO2002002632A3 (fr) Modulation de la fonction de la tetraspanine
WO2001072958A3 (fr) Peptides specifiques au cancer de la vessie utilises a des fins diagnostiques et therapeutiques
WO1996021675A3 (fr) Capture de micro-organismes a l'aide de constituants du complement
NZ514691A (en) Method to type prion proteins
ZA99445B (en) Isolated, polypeptides which bind to HLA-A29 molecules nucleic acid, the molecules encoding these, and uses thereof.
AU2001262655A1 (en) System for the preparation of monolayers of particles or molecules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase